TABRECTA (capmatinib hydrochloride)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·NON-SMALL CELL LUNG CANCER WITH MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING
Novartis Pharmaceuticals
Indication
Non-small cell lung cancer with mesenchymal-epithelial transition (MET) exon 14 skipping
Non-small cell lung cancer with mesenchymal-epithelial transition (MET) exon 14 skipping is a molecularly defined subtype of malignant epithelial lung neoplasm that primarily affects older adults with adenocarcinoma or pulmonary sarcomatoid histology. Read more about Non-small cell lung cancer with mesenchymal-epithelial transition (MET) exon 14 skipping
3 drugs 3 manufacturers
Drugs that treat it
Common Non-small cell lung cancer with mesenchymal-epithelial transition (MET) exon 14 skipping therapies.
TEPMETKO (tepotinib HCl)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·NON-SMALL CELL LUNG CANCER WITH MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING
EMD SERONO, INC
TABRECTA (capmatinib hydrochloride)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·NON-SMALL CELL LUNG CANCER WITH MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING
Novartis Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with Non-small cell lung cancer with mesenchymal-epithelial transition (MET) exon 14 skipping preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonNon-small cell lung cancer with mesenchymal-epithelial transition (MET) exon 14 skipping is a molecularly defined subtype of malignant epithelial lung neoplasm that primarily affects older adults with adenocarcinoma or pulmonary sarcomatoid histology.
It is characterized by genomic alterations affecting splice sites that lead to the in-frame deletion of exon 14 during RNA splicing.
This deletion eliminates the juxtamembrane domain binding site for the ubiquitin ligase CBL, disrupting normal proteasomal degradation and causing sustained, constitutive activation of the MET receptor tyrosine kinase pathway that drives unchecked cellular proliferation, survival, and metastasis.
- nih.gov
Non-small cell lung cancer with mesenchymal-epithelial transition (MET) exon 14 skipping is a molecularly defined subtype of malignant epithelial lung neoplasm that primarily affects older adults with adenocarcinoma or pulmonary sarcomatoid histology It is characterized by genomic alterations affecting splice sites that lead to the in-frame deletion of exon 14 during RNA splicing
- nih.gov
Non-small cell lung cancer with mesenchymal-epithelial transition (MET) exon 14 skipping is a molecularly defined subtype of malignant epithelial lung neoplasm that primarily affects older adults with adenocarcinoma or pulmonary sarcomatoid histology
- onclive.com
Non-small cell lung cancer with mesenchymal-epithelial transition (MET) exon 14 skipping is a molecularly defined subtype of malignant epithelial lung neoplasm that primarily affects older adults with adenocarcinoma or pulmonary sarcomatoid histology This deletion eliminates the juxtamembrane domain binding site for the ubiquitin ligase CBL, disrupting normal proteasomal degradation and causing sustained, constitutive activation of the MET receptor tyrosine kinase pathway that drives unchecked c...
- amegroups.org
Non-small cell lung cancer with mesenchymal-epithelial transition (MET) exon 14 skipping is a molecularly defined subtype of malignant epithelial lung neoplasm that primarily affects older adults with adenocarcinoma or pulmonary sarcomatoid histology
- nih.gov
It is characterized by genomic alterations affecting splice sites that lead to the in-frame deletion of exon 14 during RNA splicing
- nih.gov
This deletion eliminates the juxtamembrane domain binding site for the ubiquitin ligase CBL, disrupting normal proteasomal degradation and causing sustained, constitutive activation of the MET receptor tyrosine kinase pathway that drives unchecked cellular proliferation, survival, and metastasis
- nih.gov
This deletion eliminates the juxtamembrane domain binding site for the ubiquitin ligase CBL, disrupting normal proteasomal degradation and causing sustained, constitutive activation of the MET receptor tyrosine kinase pathway that drives unchecked cellular proliferation, survival, and metastasis
Personalize your experience
Follow Non-small cell lung cancer with mesenchymal-epithelial transition (MET) exon 14 skipping and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.